Welcome to our dedicated page for Liminatus Pharma SEC filings (Ticker: LIMNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liminatus Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liminatus Pharma's regulatory disclosures and financial reporting.
Liminatus Pharma, Inc. reports full-year 2025 results as a pre-clinical cancer biotech focused on a next-generation CD47 immune checkpoint inhibitor for solid tumors such as non-small cell lung cancer. The company recorded a 2025 net loss of $10.2 million and had only $337,655 in cash at year-end, leading management to raise substantial doubt about its ability to continue as a going concern.
Liminatus had an accumulated deficit of $38.9 million and no revenue, reflecting its single-asset, late-preclinical status. In November 2025 and January 2026 it received multiple Nasdaq deficiency notices related to market value and minimum bid price requirements, creating listing risk. To bolster liquidity, in February 2026 it completed a best-efforts offering of common stock, pre-funded warrants, and common warrants at $0.29 per share, raising approximately $3.46 million net.
Liminatus Pharma, Inc. updated its corporate governance rules by amending its bylaws to lower the quorum requirement for stockholder meetings. Instead of needing a majority of voting power, future meetings can proceed with one-third of the voting power present in person or by proxy.
The change applies both to overall stockholder meetings and to any required class or series votes, and allows the chair or a majority of represented shares to adjourn meetings until a quorum is reached. The amendment is effective immediately and will be submitted to stockholders for ratification, but the Board may maintain it under Delaware law even if stockholders do not approve. The full amended bylaws are included as an exhibit.
Liminatus Pharma, Inc. Schedule 13G reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC (the Reporting Persons) jointly disclose shared beneficial ownership of 2,065,885 shares of Common Stock, representing 4.99% as of 02/20/2026.
The filing states that 1,735,000 shares were to be issued at closing under a Securities Purchase Agreement and that warrants exercisable into up to 2,602,500 shares (the Intracoastal Warrant) include a blocker limiting exercises to keep ownership at or below 4.99%.
Liminatus Pharma, Inc. entered into agreements for a best-efforts public offering of common stock, pre-funded warrants and common warrants, priced at a combined $0.29 per share (or $0.2899 per pre-funded warrant) and warrant, for gross proceeds of approximately $4.0 million.
The company received net proceeds of about $3.46 million after fees and expenses, and may receive an additional $6.0 million if all investor warrants are exercised for cash. Proceeds are earmarked for clinical trials, research and development, sales and marketing, and general working capital needs.
The deal includes 8,270,000 common shares, 5,543,000 pre-funded warrants, and 13,813,000 warrants to buy up to 20,719,500 shares, plus 690,650 placement agent warrants. Liminatus and its directors agreed to 180‑day restrictions on additional equity issuance and insider sales, limiting new stock issuance and sales for that period.
Liminatus Pharma, Inc. is registering up to 6,896,551 shares of common stock, or Pre-Funded Warrants in lieu of common shares, together with accompanying warrants in a best-efforts public offering.
The company is also registering up to 6,896,551 Pre-Funded Warrants, up to 6,896,551 Warrants to purchase up to 10,344,827 shares of common stock, and up to 344,827 placement agent warrants plus 344,827 underlying shares. Each share or Pre-Funded Warrant is sold with a Warrant to buy 1.5 shares.
At an assumed combined public offering price of $1.45, Liminatus estimates net proceeds of about $9.0 million, to be used for clinical trials, research and development, sales and marketing, and general working capital. Common stock outstanding was 31,064,633 shares immediately prior to this offering and would be 37,961,184 shares immediately after, excluding any warrant exercises.
Liminatus is a pre-clinical, pre-revenue oncology company focused on a licensed CD47 checkpoint inhibitor and recently completed a SPAC-based business combination. The company reports recurring losses, substantial accumulated deficit, going-concern risks, and a material weakness in internal controls, and it qualifies as both an emerging growth and smaller reporting company, allowing reduced disclosures.
Liminatus Pharma, Inc. entered into a settlement and release agreement with Clear Street LLC on February 6, 2026. The company agreed to issue 4,000,000 shares of common stock in exchange for the surrender and cancellation of 805,377 warrants held by Clear Street.
As part of the agreement, Liminatus and Clear Street will dismiss lawsuits in the Central District of California and the Southern District of New York, where a default judgment for $7,500,000 plus approximately $515,000 in interest had been entered against Liminatus and registered in California. The share issuance was an unregistered transaction relying on the Section 3(a)(9) exemption under the Securities Act.
Liminatus Pharma, Inc. reported that on January 15, 2026 it received a deficiency notice from Nasdaq because its common stock failed to meet the Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement of $1 per share for the last 30 consecutive business days. The notice does not immediately affect the listing, and the stock will continue trading on Nasdaq under the symbol “LIMN” for now.
The company has 180 calendar days, until July 14, 2026, to regain compliance. Nasdaq would deem the company back in compliance if the closing bid price is at least $1 for a minimum of ten consecutive business days within this period. The company may also choose to implement a reverse stock split, which would need to be completed at least ten business days before the compliance period ends. If the company does not regain compliance in this initial window, it may be eligible for additional time, but there is no assurance it will meet Nasdaq’s continued listing standards.